Mdm2 inhibitors and combinations thereof

Patent metadata

Field	Value
Publication number	US-2023398115-A1
Application number	US-202318154717-A
Country	US
Kind code	A1
Filing date	Jan 13, 2023
Priority date	Aug 28, 2015
Publication date	Dec 14, 2023
Grant date	—

Abstract

The present disclosure relates to a pharmaceutical combination comprising (a) an Mdm2 inhibitor and (b)(i) a MEK inhibitor and/or (b)(ii) Bcl2 inhibitor, particularly for use in the treatment of a cancer. This disclosure also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.

First claim

1 . A pharmaceutical combination comprising
(a) (6S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-(propan-2-yl)-5,6-dihydropyrrolo[3,4-d]imidazol-4(1H)-one, or a pharmaceutically acceptable salt thereof; and (b) ABT-199, or a pharmaceutically acceptable salt thereof.

2 - 6 . (canceled)

7 . The pharmaceutical combination according to claim 1 , wherein the combination further comprises an EGFR inhibitor.

8 . The pharmaceutical combination according to claim 7 , wherein the EGFR inhibitor is selected from the group consisting of erlotinib, gefitinib, lapatinib, canertinib, pelitinib, neratinib, (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide, panitumumab, matuzumab, pertuzumab, nimotuzumab, zalutumumab, icotinib, afatinib and cetuximab, and pharmaceutically acceptable salt thereof.

9 . (canceled)

10 . The pharmaceutical combination according to claim 1 , wherein the combination further comprises a PI3K inhibitor.

11 . The pharmaceutical combination according to claim 10 , wherein the PI3K inhibitor is selected from the group consisting of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, and (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or a pharmaceutically acceptable salt thereof.

12 . The pharmaceutical combination according to claim 10 , wherein the PI3K inhibitor is an alpha-isoform specific phosphatidylinositol-3-kinase (PI3K) inhibitor (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or any pharmaceutically acceptable salt thereof.

13 . The pharmaceutical combination according to claim 1 , wherein the combination further comprises a BRAF inhibitor.

14 . The pharmaceutical combination according to claim 13 , wherein the BRAF inhibitor is selected from the group consisting of RAF265, dabrafenib, (S)-methyl-1-(4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate, methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate and vemurafenib, or a pharmaceutically acceptable salt thereof.

15 . (canceled)

16 . The pharmaceutical combination according to claim 1 , wherein the combination further comprises a CD4/6 inhibitor.

17 . The pharmaceutical combination according to claim 16 , wherein the CD4/6 inhibitor is 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, or pharmaceutically acceptable salt thereof.

18 . The pharmaceutical combination according to claim 1 , wherein the combination further comprises paclitaxel.

19 . The pharmaceutical combination according to claim 13 , wherein the combination further comprises a cMET inhibitor.

20 . (canceled)

21 . The pharmaceutical combination according to claim 1 for simultaneous or sequential use.

22 - 27 . (canceled)

28 . A method for treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical combination according to claim 1 .

29 . The method according to claim 28 , wherein the cancer is a solid tumor.

30 . The the method according to claim 28 , wherein the cancer is selected from the group consisting of a benign or malignant tumor of the lung (including small cell lung cancer and non-small-cell lung cancer), bronchus, prostate, breast (including sporadic breast cancers and sufferers of Cowden disease), pancreas, gastrointestinal tract, colon, rectum, colon carcinoma, colorectal cancer, thyroid, liver, biliary tract, intrahepatic bile duct, hepatocellular, adrenal gland, stomach, gastric, glioma, glioblastoma, endometrial, kidney, renal pelvis, bladder, uterus, cervix, vagina, ovary, multiple myeloma, esophagus, neck or head, brain, oral cavity and pharynx, larynx, small intestine, a melanoma, villous colon adenoma, a sarcoma, a neoplasia, a neoplasia of epithelial character, a mammary carcinoma, basal cell carcinoma, squamous cell carcinoma, actinic keratosis, polycythemia vera, essential thrombocythemia, a leukemia (including acute myelogenous leukemia, chronic myelogenous leukemia, lymphocytic leukemia, and myeloid leukemia), a lymphoma (including non-Hodgkin lymphoma and Hodgkin's lymphoma), myelofibrosis with myeloid metaplasia, Waldenstroem disease, and Barret's adenocarcinoma.

31 . The method according to claim 28 , wherein the cancer is a colorectal cancer, liposarcoma, glioblastoma, neuroblastoma, lymphoma, leukemia or melanoma.

32 . (canceled)

33 . (canceled)

34 . The method according to claim 28 , wherein the cancer comprises functional p53 or wild-type TP53.

35 . The method according to claim 28 , wherein the cancer comprises one or more of KRAS mutation and/or BRAF mutation and/or MEK1 mutation and/or PIK3CA mutation and/or PIK3CA overexpression.

36 - 41 . (canceled)

Assignees

• Novartis Ag

Inventors

• Caponigro Giordano
• Halilovic Ensar
• Horn-Spirohn Thomas
• Lehar Joseph

Classifications

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title

• A61K31/496 Primary

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title

• A61K31/519 Primary

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K31/5375

  1,4-Oxazines, e.g. morpholine · CPC title

• A61P35/00

  Antineoplastic agents · CPC title